Zhang Pengfei, Yang Dexin, Xiao Jiahai, Hong Weitao, Sun Huimin, Xie Qingqing, Zeng Changchun
Department of Medical Laboratory, Shenzhen Longhua District Central Hospital, Shenzhen, Guangdong 518110, China.
Department of Biochemistry and Molecular Biology, School of Basic Medicine, Guangdong Medical University, Dongguan 523808, China.
Int J Biol Macromol. 2024 Dec;282(Pt 5):136779. doi: 10.1016/j.ijbiomac.2024.136779. Epub 2024 Oct 21.
Artemisia argyi polysaccharide (AAP) is a homogeneous polysaccharide with a molecular weight of 16 kDa, displaying anti-inflammatory, antioxidant, and anti-tumorigenic properties, and potential protective effects on intestinal barrier function. It is anticipated to serve as an efficient component in diarrhea treatment. This study aims to examine the impact of AAP on diarrhea severity, intestinal barrier function, and inflammation in diarrhea-induced rats. The results demonstrated that AAP treatment notably decreased the incidence of diarrhea, reduced its severity, and lowered the disease activity score in rats, while also increasing body weight. Oral administration of AAP augmented goblet cell counts and elevated mucin-2 expression, aiding in the restoration of the mucus barrier. Additionally, AAP treatment enhanced colonic microbial diversity by increasing the abundance of S24-7 and Lactobacillus, while decreasing the levels of Bacteroides, Clostridium, and Sutterella. Moreover, the AAP administration elevated the levels of steroid hormones, prostaglandins, and their derivatives. By inhibiting the TLR4/MyD88/NF-κB pathway, AAP mitigated the release of pro-inflammatory cytokines (IL-1β, IL-6, and TNF-α) and increased the secretion of anti-inflammatory factor (IL-10). Overall, oral AAP administration effectively combats osmotic diarrhea by fortifying mucus barrier integrity and exerting anti-inflammatory effects, suggesting its potential use as an adjunctive agent in oral rehydration therapy.
艾叶多糖（AAP）是一种分子量为16千道尔顿的均一多糖，具有抗炎、抗氧化和抗肿瘤特性，对肠道屏障功能具有潜在保护作用。预计它将成为腹泻治疗中的一种有效成分。本研究旨在探讨AAP对腹泻诱导大鼠的腹泻严重程度、肠道屏障功能和炎症的影响。结果表明，AAP治疗显著降低了大鼠腹泻的发生率，减轻了腹泻严重程度，降低了疾病活动评分，同时还增加了体重。口服AAP增加了杯状细胞数量，提高了黏蛋白-2的表达，有助于黏液屏障的恢复。此外，AAP治疗通过增加S24-7和乳杆菌的丰度，同时降低拟杆菌、梭菌和萨特氏菌的水平，增强了结肠微生物多样性。此外，AAP给药提高了类固醇激素、前列腺素及其衍生物的水平。通过抑制TLR4/MyD88/NF-κB途径，AAP减轻了促炎细胞因子（IL-1β、IL-6和TNF-α）的释放，并增加了抗炎因子（IL-10）的分泌。总体而言，口服AAP通过加强黏液屏障完整性和发挥抗炎作用有效对抗渗透性腹泻，表明其在口服补液治疗中作为辅助药物的潜在用途。
